Drugs / Sepranolone

Trials 3

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 23 trials
Phase 2 NCT05434546 Feb 2022 → Feb 2023 Tourette syndrome Asarina Pharma Completed No outcome recorded
Phase 2 NCT04102995 Aug 2019 → May 2021 migraine disorder Asarina Pharma Completed No outcome recorded
Phase 2 NCT03697265 Apr 2018 → Jul 2020 premenstrual dysphoric disorder Asarina Pharma Completed No outcome recorded
Comparator or background therapy1 trial
Phase 1/2 NCT01875718 Comparator Jan 2013 → Jun 2014 premenstrual dysphoric disorder Umecrine Mood AB Completed No outcome recorded

Press releases naming this drug 1 release

DateIssuerRelease
2026-06-11 Relmada Therapeutics, Inc. Relmada Therapeutics Appoints CNS Drug Development Veteran Michael Quirk as Senior Advisor for Sepranolone Program relmada.com ↗

Evidence & citations 11 cited values

Every value below carries the sentence it was read from. 5 sources stand behind the page.

FieldValueCited text
Known as Sepranolone ClinicalTrials.gov intervention name — accepted as the source's own label NCT05434546 ↗
2

NCT04102995 ↗

NCT03697265 ↗

Known as Allopregnan-3.beta.-ol-20-one ChEMBL registry synonym — accepted as the source's own label CHEMBL2057301 ↗
Known as Epiallopregnanolone ChEMBL registry synonym — accepted as the source's own label CHEMBL2057301 ↗
Known as Isoallopregnanolone ChEMBL registry synonym — accepted as the source's own label CHEMBL2057301 ↗
Known as Isopregnanolone ChEMBL registry synonym — accepted as the source's own label CHEMBL2057301 ↗
Known as NSC-97078 ChEMBL registry synonym — accepted as the source's own label CHEMBL2057301 ↗
Known as Sepranolona ChEMBL registry synonym — accepted as the source's own label CHEMBL2057301 ↗
Known as U-0949 ChEMBL registry synonym — accepted as the source's own label CHEMBL2057301 ↗
Known as UC1010 ClinicalTrials.gov intervention name — accepted as the source's own label NCT01875718 ↗
Modality Small molecule “Sepranolone is an endogenous steroid.” NCT03697265 ↗
Route Subcutaneous “UC1010 when administered subcutaneously as a single dose” NCT01875718 ↗